Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis.
Saved in:
| Title: | Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis. |
|---|---|
| Authors: | Zhou J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China., Xing L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Miao Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Qin S; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Zhang R; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Tang H; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Xu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China., Xia Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com., Zhu H; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com., Li J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com. |
| Source: | Investigational new drugs [Invest New Drugs] 2025 Jun; Vol. 43 (3), pp. 451-459. Date of Electronic Publication: 2025 May 31. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40450180 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Zhou+J%22">Zhou J</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Xing+L%22">Xing L</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Miao+Y%22">Miao Y</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Qin+S%22">Qin S</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Zhang+R%22">Zhang R</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Tang+H%22">Tang H</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Xu+W%22">Xu W</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Xia+Y%22">Xia Y</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. cynthia0311@163.com.<br /><searchLink fieldCode="AU" term="%22Zhu+H%22">Zhu H</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. huayuan.zhu@hotmail.com.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2025 Jun; Vol. 43 (3), pp. 451-459. <i>Date of Electronic Publication: </i>2025 May 31. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40450180 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10637-025-01542-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 451 Titles: – TitleFull: Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zhou J – PersonEntity: Name: NameFull: Xing L – PersonEntity: Name: NameFull: Miao Y – PersonEntity: Name: NameFull: Qin S – PersonEntity: Name: NameFull: Zhang R – PersonEntity: Name: NameFull: Tang H – PersonEntity: Name: NameFull: Xu W – PersonEntity: Name: NameFull: Xia Y – PersonEntity: Name: NameFull: Zhu H – PersonEntity: Name: NameFull: Li J IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2025 Jun Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1573-0646 Numbering: – Type: volume Value: 43 – Type: issue Value: 3 Titles: – TitleFull: Investigational new drugs Type: main |
| ResultId | 1 |
